Title: Rodger P Mcever: Innovator in Anti-P-Selectin Antibodies
Introduction
Rodger P Mcever is a notable inventor in the field of biomedical research, particularly known for his work on anti-P-selectin antibodies. His innovative contributions have the potential to impact the treatment of various inflammatory and thrombotic disorders. Despite having no patents to his name, his research has laid the groundwork for future developments in this area.
Latest Patents
Rodger P Mcever's significant work includes the disclosure of antibodies that specifically bind to P-selectin. These antibodies block the binding of PSGL-1 to P-selectin and facilitate the dissociation of preformed P-selectin/PSGL-1 complexes. The research identifies a previously unrecognized near N-terminal antibody binding domain of P-selectin, which is crucial for the functionality of these antibodies. The dual function of these anti-P-selectin antibodies may be utilized in treating a variety of acute and chronic inflammatory and thrombotic conditions.
Career Highlights
Throughout his career, Rodger P Mcever has been associated with prominent research institutions. He has worked at the Oklahoma Medical Research Foundation and Selexys Pharmaceuticals Corporation, where he has contributed to significant advancements in medical research. His expertise in the field has made him a respected figure among his peers.
Collaborations
Rodger P Mcever has collaborated with notable colleagues, including Scott A Rollins and Richard Alvarez. These collaborations have further enriched his research and contributed to the development of innovative solutions in the biomedical field.
Conclusion
Rodger P Mcever's work on anti-P-selectin antibodies represents a significant advancement in the treatment of inflammatory and thrombotic disorders. His contributions, although not patented, are vital to the ongoing research and development in this important area of medicine.